Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.
We performed post-marketing surveillance to evaluate the safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART). In total, 356 CART sessions in 147 patients at 22 centers were performed. The most common primary disease was cancer (128 cases, 300 sessions). Mean amount of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0177303&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849766185920364544 |
|---|---|
| author | Norio Hanafusa Ayako Isoai Tomoaki Ishihara Tetsuya Inoue Ken Ishitani Taiju Utsugisawa Toshihiko Yamaka Tetsuya Ito Hiroshi Sugiyama Atsushi Arakawa Yosuke Yamada Yasuo Itano Hirokazu Onodera Ryosuke Kobayashi Naoko Torii Toyoko Numata Taihei Kashiwabara Yoshihiro Matsuno Michio Kato |
| author_facet | Norio Hanafusa Ayako Isoai Tomoaki Ishihara Tetsuya Inoue Ken Ishitani Taiju Utsugisawa Toshihiko Yamaka Tetsuya Ito Hiroshi Sugiyama Atsushi Arakawa Yosuke Yamada Yasuo Itano Hirokazu Onodera Ryosuke Kobayashi Naoko Torii Toyoko Numata Taihei Kashiwabara Yoshihiro Matsuno Michio Kato |
| author_sort | Norio Hanafusa |
| collection | DOAJ |
| description | We performed post-marketing surveillance to evaluate the safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART). In total, 356 CART sessions in 147 patients at 22 centers were performed. The most common primary disease was cancer (128 cases, 300 sessions). Mean amount of ascites collected was 3.7 L, and mean concentration ratio was 9.2. Mean amount of reinfused protein was 67.8 g (recovery rate, 72.0%). Performance status, dietary intake, urine volume, body weight and abdominal circumference were significantly improved after CART. Body temperature increased significantly, by 0.3°C on average. Concomitant steroids and/or NSAIDs use before reinfusion was significantly and negatively associated with increases in body temperature. Most adverse events were fever and chills. This study examined a large number of patients compared with previous studies, and showed that CART is an effective and relatively safe treatment for refractory ascites, such as malignant ascites. |
| format | Article |
| id | doaj-art-7affb2ecce05439796224d035af5cf8b |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-7affb2ecce05439796224d035af5cf8b2025-08-20T03:04:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01125e017730310.1371/journal.pone.0177303Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.Norio HanafusaAyako IsoaiTomoaki IshiharaTetsuya InoueKen IshitaniTaiju UtsugisawaToshihiko YamakaTetsuya ItoHiroshi SugiyamaAtsushi ArakawaYosuke YamadaYasuo ItanoHirokazu OnoderaRyosuke KobayashiNaoko ToriiToyoko NumataTaihei KashiwabaraYoshihiro MatsunoMichio KatoWe performed post-marketing surveillance to evaluate the safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART). In total, 356 CART sessions in 147 patients at 22 centers were performed. The most common primary disease was cancer (128 cases, 300 sessions). Mean amount of ascites collected was 3.7 L, and mean concentration ratio was 9.2. Mean amount of reinfused protein was 67.8 g (recovery rate, 72.0%). Performance status, dietary intake, urine volume, body weight and abdominal circumference were significantly improved after CART. Body temperature increased significantly, by 0.3°C on average. Concomitant steroids and/or NSAIDs use before reinfusion was significantly and negatively associated with increases in body temperature. Most adverse events were fever and chills. This study examined a large number of patients compared with previous studies, and showed that CART is an effective and relatively safe treatment for refractory ascites, such as malignant ascites.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0177303&type=printable |
| spellingShingle | Norio Hanafusa Ayako Isoai Tomoaki Ishihara Tetsuya Inoue Ken Ishitani Taiju Utsugisawa Toshihiko Yamaka Tetsuya Ito Hiroshi Sugiyama Atsushi Arakawa Yosuke Yamada Yasuo Itano Hirokazu Onodera Ryosuke Kobayashi Naoko Torii Toyoko Numata Taihei Kashiwabara Yoshihiro Matsuno Michio Kato Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. PLoS ONE |
| title | Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. |
| title_full | Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. |
| title_fullStr | Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. |
| title_full_unstemmed | Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. |
| title_short | Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. |
| title_sort | safety and efficacy of cell free and concentrated ascites reinfusion therapy cart in refractory ascites post marketing surveillance results |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0177303&type=printable |
| work_keys_str_mv | AT noriohanafusa safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT ayakoisoai safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT tomoakiishihara safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT tetsuyainoue safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT kenishitani safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT taijuutsugisawa safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT toshihikoyamaka safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT tetsuyaito safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT hiroshisugiyama safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT atsushiarakawa safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT yosukeyamada safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT yasuoitano safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT hirokazuonodera safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT ryosukekobayashi safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT naokotorii safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT toyokonumata safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT taiheikashiwabara safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT yoshihiromatsuno safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults AT michiokato safetyandefficacyofcellfreeandconcentratedascitesreinfusiontherapycartinrefractoryascitespostmarketingsurveillanceresults |